Sign in
CERO Stock Price, Chart, Stats & News
CERo Therapeutics Holdings, Inc.
Save
CERo Therapeutics Holdings, Inc. (CERO) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
CERO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -19.65% |
Operating margin | -1310.19% |
Pretax margin | -1215.62% |
Net margin | -1215.60% |
Effective tax rate | – |
ROA | -361.39% |
ROE | 673.03% |
D/E | -0.20x |
Interest coverage ratio | 572.62x |
CERO valuation
P/E | – |
P/S | 0.03x |
P/B | -0.01x |
P/CF | -0.01x |
P/FCF | -0.00x |
P/OCF | -0.01x |
PEG | -0.00x |
EV multiple | -0.09x |
About
CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. This company was founded in 2021 and is headquartered in South San Francisco, California.
Similar securities
Based on sector and market capitalization
Report issue